A Phase 2 interventional study of Faricimab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.
Among the 13 studies testing faricimab in Macular Edema, this one is the 10th largest by enrollment, is one of 2 that started in 2020, is one of 2 in phase 2, and was the 6th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2020.
This study's enrollment of 99 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 229 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 14th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
2 of the studies testing faricimab in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing faricimab in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular Exclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Fellow Eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 6 doses (one 6 mg faricimab intravitreal \[IVT\] injection every 28 days \[Q4W\]) starting at Day 1 and ending on the Day 140 visit. Participants will return for a safety follow-up visit (SFV) after ≥28 days and within \<35 days following their last study treatment.
Drug: Faricimab
A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Also known as: VABYSMO™, RO6867461, RG7716
Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24
The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a ≥2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug.
Time frame: Baseline and Week 24
Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for visit, age (continuous), baseline BCVA (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.
Time frame: From Baseline to Week 24
Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using Spectral Domain-Optical Coherence Tomography (SD-OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model was adjusted for visit, age (continuous), baseline CST (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.
Time frame: From Baseline to Week 24
Median Time to First Absence of DME in the Study Eye During the Study
An event was defined as the first absence of diabetic macular edema (DME) in the study eye, defined as first time reaching central subfield thickness (CST; ILM-RPE) \<305 microns, after baseline. Baseline was defined as the participant's last observation prior to initiation of study drug. The time to first absence of DME was a Kaplan-Meier estimate. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley. Participants without an event and discontinued from treatment were censored at the last CST assessment.
Time frame: From Baseline to Week 24
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24
The absence of intraretinal fluid (IRF) in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of IRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.
Time frame: Week 24
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24
The absence of subretinal fluid (SRF) in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of SRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.
Time frame: Week 24
A total of 99 patients were enrolled in the study at 23 sites in 7 countries.
| Milestone | Faricimab |
|---|---|
| Started | 99 |
| Completed | 89 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Death | 1 |
The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a ≥2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug.
| Percentage of participants | Faricimab |
|---|---|
| Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24 | 50.0 (37.2 to 62.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for visit, age (continuous), baseline BCVA (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.
| ETDRS Letters | Faricimab |
|---|---|
| Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | 9.2 (7.5 to 10.9) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using Spectral Domain-Optical Coherence Tomography (SD-OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model was adjusted for visit, age (continuous), baseline CST (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.
| microns | Faricimab |
|---|---|
| Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24 | -200.2 (-214.1 to -186.2) |
An event was defined as the first absence of diabetic macular edema (DME) in the study eye, defined as first time reaching central subfield thickness (CST; ILM-RPE) \<305 microns, after baseline. Baseline was defined as the participant's last observation prior to initiation of study drug. The time to first absence of DME was a Kaplan-Meier estimate. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley. Participants without an event and discontinued from treatment were censored at the last CST assessment.
| Weeks | Faricimab |
|---|---|
| Median Time to First Absence of DME in the Study Eye During the Study | 8.0 (8.0 to 12.0) |
The absence of intraretinal fluid (IRF) in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of IRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.
| Percentage of participants | Faricimab |
|---|---|
| Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24 | 26.1 (17.3 to 36.6) |
The absence of subretinal fluid (SRF) in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of SRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.
| Percentage of participants | Faricimab |
|---|---|
| Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24 | 98.9 (93.8 to 100.0) |
Collected over From first dose of study drug until ≥28 days to <35 days after the last dose of study drug (up to 24 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faricimab | 1/99 (1%) | 8/99 (8.1%) | 21/99 (21.2%) |
| Event | Faricimab |
|---|---|
| Localised infectionInfections and infestations | 2/99 |
| SepsisInfections and infestations | 2/99 |
| COVID-19Infections and infestations | 1/99 |
| CellulitisInfections and infestations | 1/99 |
| Escherichia urinary tract infectionInfections and infestations | 1/99 |
| OsteomyelitisInfections and infestations | 1/99 |
| Acute myocardial infarctionCardiac disorders | 1/99 |
| Coronary artery diseaseCardiac disorders | 1/99 |
| Spinal operationSurgical and medical procedures | 1/99 |
| Toe amputationSurgical and medical procedures | 1/99 |
| Event | Faricimab |
|---|---|
| COVID-19Infections and infestations | 7/99 |
| Diabetic retinal oedemaEye disorders | 6/99 |
| Retinal exudatesEye disorders | 5/99 |
| HypertensionVascular disorders | 5/99 |
There were 2 analysis populations in this study, the modified intent-to-treat (mITT; all patients enrolled in the study that received any amount of study treatment) and safety-evaluable (SAF; all patients enrolled in the study who received at least 1 injection of study treatment) populations. All 99 participants were included in both the mITT and SAF populations.
| Age, Continuous(Years) | Faricimab |
|---|---|
| Mean | 59.5 ± 9.8 |
| Sex: Female, Male(Participants) | Faricimab |
|---|---|
| Female | 38 |
| Male | 61 |
| Ethnicity (NIH/OMB)(Participants) | Faricimab |
|---|---|
| Hispanic or Latino | 25 |
| Not Hispanic or Latino | 73 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Faricimab |
|---|---|
| Black or African American | 7 |
| White | 86 |
| Asian | 5 |
| Unknown | 1 |
| Region of Enrollment(Participants) | Faricimab |
|---|---|
| US and Canada | 62 |
| Rest of the World | 37 |
| Best-Corrected Visual Acuity (BCVA) in the Study Eye at Baseline(ETDRS Letters) | Faricimab |
|---|---|
| Mean | 62.5 ± 11.8 |
| Central Subfield Thickness (CST) in the Study Eye at Baseline(microns) | Faricimab |
|---|---|
| Mean | 464.0 ± 149.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing).
Ran from Nov 2020 to primary completion in Dec 2022, 24 months.
Results were first posted in Dec 2023, 11 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 24 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab